Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean‐Pascal Machiels, Ana Paula Victorina, Yungan Tao et al.|The Lancet Oncology|2024Cited by 223
Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.Robert J. Motzer, Daniel Yick Chin Heng, Yanfang Liu et al.|Journal of Clinical Oncology|2021Cited by 6